2.89

1.03% -0.03

After Hours: 2.90 0.010 +0.35%

Geron Corp (GERN)

Overview News Price History Option Chain Financials Why GERN Down? Discussions Forecast

Geron Corp stock is traded at $2.89, with a volume of 8.56M. It is down -1.03% in the last 24 hours and down -26.46% over the past month. Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Previous Close:

$2.92

Open:

$2.92

24h Volume:

8.56M

Relative Volume:

0.87

Market Cap:

$1.75B

Revenue:

$29.48M

Net Income/Loss:

$-201.19M

P/E Ratio:

-9.0313

EPS:

-0.32

Net Cash Flow:

$-216.50M

1W Performance:

-8.83%

1M Performance:

-26.46%

6M Performance:

-39.29%

1Y Performance:

+50.52%

1-Day Range:

$2.85

$2.985

1-Week Range:

$2.80

$3.102

52-Week Range:

$1.64

$5.34

Geron Corp Stock (GERN) Company Profile

Name

Geron Corp

Sector

Healthcare (1174)

Industry

Biotechnology (684)

Phone

(650) 473-7700

Address

919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA

Employee

141

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

GERN's Discussions on Twitter

Compare GERN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GERN Geron Corp	2.89	1.75B	29.48M	-201.19M	-216.50M	-0.32
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Geron Corp Stock (GERN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-24	Initiated	H.C. Wainwright	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Initiated	Leerink Partners	Outperform
Apr-30-24	Downgrade	Robert W. Baird	Outperform → Neutral
Apr-29-24	Initiated	TD Cowen	Buy
Mar-15-24	Reiterated	Needham	Buy
Sep-12-23	Upgrade	Goldman	Neutral → Buy
Mar-28-23	Initiated	Goldman	Neutral
Oct-28-22	Initiated	Wedbush	Outperform
Jul-28-22	Resumed	B. Riley Securities	Buy
Nov-02-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Resumed	B. Riley Securities	Buy
Aug-03-20	Initiated	Stifel	Buy
Nov-19-19	Resumed	B. Riley FBR	Buy
Sep-03-19	Initiated	H.C. Wainwright	Buy
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight
Apr-09-19	Upgrade	Needham	Hold → Buy
Jan-31-19	Upgrade	B. Riley FBR	Neutral → Buy
Oct-02-18	Downgrade	B. Riley FBR	Buy → Neutral
Jul-05-18	Initiated	B. Riley FBR, Inc.	Buy
Sep-13-16	Reiterated	FBR & Co.	Outperform
Sep-13-16	Reiterated	FBR Capital	Outperform
Dec-07-15	Reiterated	Piper Jaffray	Overweight
Apr-21-15	Initiated	Oppenheimer	Outperform
Jun-12-14	Upgrade	MLV & Co	Hold → Buy
Mar-12-14	Downgrade	MLV & Co	Buy → Hold
Dec-10-13	Reiterated	MLV & Co	Buy
Dec-10-13	Upgrade	Needham	Hold → Buy
Nov-08-13	Reiterated	MLV & Co	Buy
Oct-16-13	Initiated	MLV & Co	Buy
Aug-30-12	Initiated	Stifel Nicolaus	Buy
Jun-28-12	Initiated	Needham	Hold